Narrow-moat CR Pharma's interim revenue growth is slower than expected, but offset by a higher gross margin due to product mix. We tweak our 2024 annual assumptions accordingly while keeping our long-term outlook unchanged. Our fair value estimate remains at HKD 5.80 per share. We think the share price is fairly valued.
Price cuts for volume-based procurement are more lenient, raising CR Pharma’s operating margin.
The current cycle of interest-rate cuts in China reverses, leading to higher short-term interest servicing costs for CR Pharma.
|
Metric
|
03320
|
01099
|
02607
|
|---|---|---|---|
Price/Earnings (Normalized) | 7.00 | 6.43 | 9.86 |
Price/Book Value | 0.65 | 0.72 | 0.56 |
Price/Sales | 0.12 | 0.09 | 0.15 |
Price/Cash Flow | 2.60 | 3.34 | 4.11 |
|
Metric
|
03320
|
01099
|
02607
|
|---|---|---|---|
Quick Ratio | 1.03 | 1.07 | 1.02 |
Current Ratio | 1.37 | 1.35 | 1.33 |
Interest Coverage | 5.65 | 7.57 | 5.24 |
|
Metric
|
03320
|
01099
|
02607
|
|---|---|---|---|
Return on Assets (Normalized) | 3.88% | 3.87% | 1.90% |
Return on Equity (Normalized) | 21.04% | 21.65% | 5.98% |
Return on Invested Capital (Normalized) | 6.76% | 8.28% | 3.83% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Zoetis Inc Class A
ZTS
| Pyztqrhkqp | Gtdq | $88.3 Bil | |||
| Merck KGaA ADR
MKKGY
| Smtgcrfww | Hfpgz | $77.4 Bil | |||
| Haleon PLC ADR
HLN
| Mlphppmy | Gjj | $47.3 Bil | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| Vbcrskl | Gbw | $19.0 Bil | |||
| Viatris Inc
VTRS
| Tbmstdbrd | Fjf | $13.9 Bil | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Brgcbfcq | Vnvcm | $13.4 Bil | |||
| Catalent Inc
CTLT
| Brjfgvvtl | Tljxcss | $10.9 Bil | |||
| Prestige Consumer Healthcare Inc
PBH
| Wfcsvpv | Svshrjh | $3.5 Bil | |||
| Perrigo Co PLC
PRGO
| Ltflxjgdn | Wxkw | $3.5 Bil | |||
| Green Thumb Industries Inc
GTBIF
| Wgjykfccr | Bqp | $2.5 Bil |
United States